ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma

Clinical Pharmacokinetics · Published 2026-06-23 · DOI 10.1007/s40262-026-01662-0

Free full text

Authors (20)

Kosuke Suzuki, Yumi Otoyama, Natsumi Matsumoto, Yusuke Masuo, Yoko Nakajima, Ikuya Sugiura, Takahiro Fuji, Erika Nomura, Yuki Ichikawa, Yuu Shimozuma, Manabu Uchikoshi, Momoka Hayano, Mayuko Hanano, Remi Murase, Chika Mitomori, Kiyoshi Oka, Masashi Sakaki, Yukio Kato, Hitoshi Yoshida, Ken-ichi Fujita

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Suzuki, K., Otoyama, Y., Matsumoto, N., et al. (2026). ALBI Grade is a Determinant of Lenvatinib Pharmacokinetics, Efficacy, and Toxicities in Japanese Patients with Hepatocellular Carcinoma. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-026-01662-0

Related articles